HUMA Stock Price, Humacyte, Inc. Quote, Chart

Market Summary

USD6.33-0.09

Market Closed

-1.40%

HUMA Stock Price

View Fullscreen

HUMA RSI Chart

HUMA Valuation

Market Cap

753.8M

Price/Earnings (Trailing)

-7.13

Price/Sales (Trailing)

481.66

Price/Free Cashflow

-9.03

HUMA Price/Sales (Trailing)

HUMA Profitability

Return on Equity

-404.19%

Return on Assets

-65.46%

Free Cashflow Yield

-11.07%

HUMA Fundamentals

HUMA Revenue

Revenue (TTM)

1.6M

HUMA Earnings

Earnings (TTM)

-105.7M

Earnings Growth (Yr)

13.72%

Earnings Growth (Qtr)

-27.05%

Breaking Down HUMA Revenue

Last 7 days

34.5%

Last 30 days

102.6%

Last 90 days

43.0%

Trailing 12 Months

50.1%

How does HUMA drawdown profile look like?

HUMA Financial Health

Current Ratio

8.37

HUMA Investor Care

Shares Dilution (1Y)

15.25%

Diluted EPS (TTM)

-1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	1.3M	2.0M	1.7M	1.6M
2021	3.7M	2.9M	2.1M	1.3M
2020	0	0	5.4M	4.5M
2019	0	0	0	6.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Humacyte, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 21, 2023	wallace max n.	acquired	7,811	1.19	6,564	-
Oct 10, 2023	niklason laura e	acquired	136,160	1.19	114,420	president, ceo and director
Oct 10, 2023	dougan brady w	acquired	136,160	1.19	114,420	-
Sep 14, 2023	niklason laura e	sold	-5,560,000	2.78	-2,000,000	president, ceo and director
Sep 14, 2023	dougan brady w	sold	-5,560,000	2.78	-2,000,000	-
Aug 21, 2023	ayabudge llc	sold	-2,042,280	3.39	-602,443	-
Aug 21, 2023	dougan brady w	sold	-2,042,280	3.39	-602,443	-
Aug 21, 2023	niklason laura e	sold	-2,042,280	3.39	-602,443	president, ceo and director
Aug 18, 2023	niklason laura e	sold	-2,238,320	3.57	-626,979	president, ceo and director
Aug 18, 2023	ayabudge llc	sold	-2,238,320	3.57	-626,979	-

Which funds bought or sold HUMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-59.41	-4,084	3,269	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-9,476	19,151	-%
May 16, 2024	JANE STREET GROUP, LLC	unchanged	-	9,205	30,000	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-7.8	936	98,087	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	reduced	-47.11	-51,797	71,281	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	615,979	615,979	-%
May 15, 2024	MORGAN STANLEY	reduced	-8.71	-149	436,430	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-50.78	-104,715	122,431	-%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-3.83	4,449	88,144	-%
May 15, 2024	WOLVERINE TRADING, LLC	reduced	-7.92	491	58,972	-%

Are Funds Buying or Selling HUMA?

Are funds buying HUMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HUMA

No. of Funds

Unveiling Humacyte, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2024	niklason laura e	8.4%	10,153,195	SC 13D/A
Mar 07, 2024	fresenius medical care holdings inc /ny/	15.4%	18,312,735	SC 13D/A
Dec 01, 2023	fresenius medical care holdings inc /ny/	-	0	SC 13D/A
Sep 15, 2023	niklason laura e	9.5%	10,050,822	SC 13D/A
Aug 22, 2023	niklason laura e	11.1%	11,612,809	SC 13D/A
Jun 15, 2023	niklason laura e	13.2%	13,911,388	SC 13D/A
May 26, 2023	niklason laura e	17.9%	18,786,211	SC 13D/A
Sep 19, 2022	niklason laura e	21.3%	22,336,411	SC 13D/A
Feb 14, 2022	glazer capital, llc	0.0%	0	SC 13G/A
Feb 09, 2022	parian global management lp	0%	0	SC 13G/A

Recent SEC filings of Humacyte, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 13, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	10-K	Annual Report
Mar 22, 2024	8-K	Current Report
Mar 08, 2024	SC 13D/A	13D - Major Acquisition
Mar 07, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Humacyte, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Humacyte, Inc. News

Latest updates

Humacyte, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	-	-	-	-	-	31.00	1,301	233	177	241	690	-	-	-	-
Operating Expenses	1.5%	26,578	26,182	22,512	20,790	23,525	19,832	21,996	21,804	20,784	19,959	19,924	15,796	18,127	-
S&GA Expenses	-100.0%	-	6,002	5,234	5,833	6,188	5,180	5,682	5,554	5,398	5,391	4,787	2,597	3,435	-
R&D Expenses	5.4%	21,264	20,180	17,278	14,957	17,337	14,652	16,314	16,250	15,386	14,568	15,137	13,199	14,692	-
Interest Expenses	5.2%	1,816	1,727	1,699	1,639	1,641	1,488	1,432	1,396	1,204	1,215	533	541	549	-
Net Income	-27.0%	-31,896	-25,106	-36,969	-3,720	-25,281	36,868	-19,832	42,585	-31,563	-17,198	-20,301	-16,212	-17,760	-
Net Income Margin	4.6%	-67.54*	-70.78*	-18.60*	-7.65*	19.71*	14.37*	-19.39*	-20.96*	-40.92*	-24.61*	-18.56*	-	-	-
Free Cashflow	-44.6%	-27,691	-19,150	-19,793	-19,640	-17,015	-16,700	-18,822	-21,535	-30,583	-14,720	-14,572	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	25.9%	161	128	149	168	183	204	226	246	264	287	303	101	101	107	101	169
Current Assets	41.6%	118	83.00	103	121	134	154	175	193	209	229	244	0.00	1.00	41.00	1.00	95.00
Cash Equivalents	44.0%	116	80.00	100	115	130	150	164	181	198	218	240	29.00	45.00	40.00	55.00	94.00
Net PPE	-4.2%	26.00	27.00	28.00	29.00	30.00	30.00	31.00	32.00	34.00	35.00	36.00	38.00	-	41.00	-	47.00
Liabilities	18.0%	135	115	112	107	101	87.00	108	104	161	164	228	17.00	17.00	36.00	36.00	36.00
Current Liabilities	-23.6%	14.00	18.00	15.00	11.00	24.00	20.00	18.00	11.00	11.00	11.00	21.00	0.00	0.00	11.00	0.00	11.00
Shareholder's Equity	93.1%	26.00	14.00	37.00	61.00	82.00	117	119	142	104	122	76.00	5.00	5.00	5.00	5.00	-
Retained Earnings	-5.9%	-569	-537	-512	-486	-463	-426	-422	-397	-434	-414	-457	-7.73	-8.02	-388	-0.04	-321
Additional Paid-In Capital	8.1%	595	551	549	547	545	543	541	540	538	537	533	13.00	13.00	38.00	5.00	33.00
Shares Outstanding	14.9%	119	104	103	103	103	103	103	103	103	103	19.00	6.00	6.00	-	-	-
Float	-	-	-	-	178	-	-	-	166	-	-	-	102	-	102	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-43.7%	-27,300	-19,000	-13,056	-22,603	-18,641	-18,959	-16,804	-16,566	-18,800	-21,490	-30,500	-14,657	-14,543	-7,727	-18.05	-	-
Share Based Compensation	3.4%	1,454	1,406	1,772	1,841	1,809	1,670	1,476	1,491	1,547	2,811	1,877	2,930	2,528	1,228	1,170	-	-
Cashflow From Investing	-160.7%	-391	-150	-493	1,622	-1,152	5,212	-211	-134	-22.00	-8,045	-83.00	-63.00	-29.00	-6.50	-100,000	-	-
Cashflow From Financing	18844.8%	62,795	-335	-764	6,015	-409	-212	-289	-484	-461	6,546	242,082	-916	19,271	-160	101,334	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HUMA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	21,264	17,278
General and administrative	5,314	5,234
Total operating expenses	26,578	22,512
Loss from operations	(26,578)	(22,512)
Other income (expense), net:
Interest income	1,031	1,475
Change in fair value of Contingent Earnout Liability	(4,593)	(14,191)
Interest expense	(1,816)	(1,699)
Change in fair value of derivative liabilities	60	(42)
Total other expense, net	(5,318)	(14,457)
Net loss	(31,896)	(36,969)
Comprehensive loss	$ (31,896)	$ (36,969)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.29)	$ (0.36)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.29)	$ (0.36)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares)	108,246,008	103,263,528
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares)	108,246,008	103,263,528

HUMA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 115,505	$ 80,448
Prepaid expenses and other current assets	2,421	2,830
Total current assets	117,926	83,278
Property and equipment, net	25,653	26,791
Finance lease right-of-use assets, net	17,059	17,313
Other long-term assets	828	841
Total assets	161,466	128,223
Current liabilities
Accounts payable	3,452	6,490
Accrued expenses	7,917	9,340
Finance lease obligation, current portion	2,663	2,560
Operating lease obligation, current portion	55	53
Total current liabilities	14,087	18,443
Revenue interest liability	57,959	38,600
Contingent Earnout Liability	42,509	37,916
Finance lease obligation, net of current portion	15,850	16,293
Contingent derivative liability	4,079	2,636
Other long-term liabilities	830	789
Total liabilities	135,314	114,677
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.0001 par value; 20,000,000 shares designated as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 119,084,353 and 103,673,728 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	12	10
Additional paid-in capital	595,350	550,850
Accumulated deficit	(569,210)	(537,314)
Total stockholders’ equity	26,152	13,546
Total liabilities and stockholders’ equity	$ 161,466	$ 128,223

About Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

CEO	Dr. Laura E. Niklason M.D., Ph.D.
WEBSITE	humacyte.com
INDUSTRY	Biotechnology
EMPLOYEES	164

Humacyte, Inc. Frequently Asked Questions

What is the ticker symbol for Humacyte, Inc.? What does HUMA stand for in stocks?

HUMA is the stock ticker symbol of Humacyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Humacyte, Inc. (HUMA)?

As of Fri May 17 2024, market cap of Humacyte, Inc. is 752.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HUMA stock?

You can check HUMA's fair value in chart for subscribers.

What is the fair value of HUMA stock?

You can check HUMA's fair value in chart for subscribers. The fair value of Humacyte, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Humacyte, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HUMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Humacyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether HUMA is over valued or under valued. Whether Humacyte, Inc. is cheap or expensive depends on the assumptions which impact Humacyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HUMA.

What is Humacyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HUMA's PE ratio (Price to Earnings) is -7.12 and Price to Sales (PS) ratio is 416.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HUMA PE ratio will change depending on the future growth rate expectations of investors.